Although c-MYC signaling is associated with aggressive neoplasms, we recently demonstrated the prevalence of c-MYC/PLK1 signaling in nodular lymphocyte predominant B-cell lymphoma (NLPHL), an indolent B-cell lymphoma subtype [37]. The gene discussed is MYC; the disease is neoplasm.